Baxter's Vepacel flu vaccine approved in Europe; Medicago and Mitsubishi Tanabe hook up for vaccine R&D deal;

> Baxter has received marketing approval in Europe for its inactivated adult influenza vaccine, Vepacel. Press release

> Bavarian Nordic has submitted its smallpox vaccine for marketing approval in Europe, where it will be marketed as Imvanex. Press release

> Medicago and Mitsubishi Tanabe have signed a $33 million deal to develop at least three new vaccines, including a rotavirus vaccine. Press release

> Nuron Biotech has licensed in rights to Akshaya Bio's Chimigen multi-antigen hepatitis B vaccines, as well as an option to license prophylactic and therapeutic products for the hepatitis C virus. Press release

> iBio, a biopharma company that develops plant-based products, has received a patent for its technology to enhance the effectiveness of vaccines. Article

> Novavax's ($NVAX) flu shot has begun Phase II clinical trials, with data expected in the third quarter. Press release

> A Cuban hepatitis B vaccine is in clinical trials, which are "almost finished." Article

> The University of Cincinnati is carrying out a Phase II trial of an ovarian cancer vaccine. Press release

> Researchers in Ireland are conducting the country's first ever malaria vaccine clinical trial, and results are expected later this year. Press release

> Intercell ($ICLL) has begun the second part of its Phase I clostridium vaccine trial. Press release

> Panacea Biotec has withdrawn its oral polio vaccine from the WHO's list of pre-qualified vaccines because of manufacturing issues. Article

And Finally… The current anti-smoking shots in development are not likely to be cost-effective, according to an Australian study. Story

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.